- Global Pharma News & Resources

Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022

STORM recognised as an innovative early-stage biotechnology company pioneering novel drug targets

12 September 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes for oncology and other diseases, is pleased to announce that Fierce Biotech has named it as one of its 2022 “Fierce 15”, designating it as one of the most exciting biotechnology companies in the industry. This award highlights STORM’s dedication to developing novel treatments for the unmet medical need of patients, and its successes at the forefront of the RNA modification field.

Dr. Jerry McMahon, CEO of STORM Therapeutics added: “We are thrilled to be named among the industry’s most exciting biotech companies.  As the first ever biotech to put a targeted RNA-modifying enzyme (RME) inhibitor into the clinic, it is an honor that STORM’s focus to become the global leader in our field of RME has been recognized. We look forward to continuing the progression of STORM by advancing our first-in-class candidate STC-15 into clinical development and bring forward our pipeline of drug candidates next year for oncology and other disease indications.

STORM’s first-in-class clinical candidate STC-15, an orally bioavailable, highly selective METTL3 inhibitor, is on track to begin initial clinical studies in solid tumors in 2022 and will be the first molecule specifically targeting an RNA modifying enzyme to enter clinical development. In 2021, STORM also entered into a significant drug discovery partnership with a leading oncology company to target the RNA editor ADAR1.

The Fierce 15 awards celebrate the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.  This is Fierce Biotech’s 20th annual Fierce 15 selection. 

An internationally recognized daily report reaching a network of over 450,000 biotech and pharma industry professionals, Fierce Biotech provides subscribers with an authoritative analysis of the day's top stories. Every year Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and competitive market position.

Editor Details

Related Links

Last Updated: 12-Sep-2022